: Pharmacological combinations using immune checkpoint inhibition (ICI), tyrosine kinase inhibition (TKIs) and mammalian target of rapamycin inhibitors (mTOR), have improved survival in metastatic clear cell renal cell cancer (mccRCC).
: Pharmacological combinations using immune checkpoint inhibition (ICI), tyrosine kinase inhibition (TKIs) and mammalian target of rapamycin inhibitors (mTOR), have improved survival in metastatic clear cell renal cell cancer (mccRCC).